tilatamig samrotecan (AZD9592) / AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tilatamig samrotecan (AZD9592) / AstraZeneca
EGRET, NCT05647122: First in Human Study of AZD9592 in Solid Tumors

Recruiting
1
162
Europe, Canada, Japan, US, RoW
AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
AstraZeneca
Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
12/25
12/25

Download Options